Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
portion decrease » proportional decrease (Expand Search)
point decrease » point increase (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
portion decrease » proportional decrease (Expand Search)
point decrease » point increase (Expand Search)
-
1841
DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021.
Published 2025Subjects: -
1842
-
1843
-
1844
-
1845
-
1846
-
1847
-
1848
-
1849
-
1850
-
1851
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1852
-
1853
CHAMPS pilot Hb dataset.
Published 2025“…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
-
1854
-
1855
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1856
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1857
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1858
-
1859
-
1860